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Alpha interferon (IFN-a) restricts multiple steps of the human immunodeficiency virus type 1 (HIV-i) life
cycle. A well-described effect of IFN-a is in the modulation of viral nucleic acid synthesis. We demonstrate that
IFN-a influences HIV-1 DNA synthesis principally by reducing the production of late products of reverse
transcription. The magnitude of IFN-ot-induced downregulation of HIV-1 DNA and/or progeny virion
production was dependent on the IFN-ot concentration, the duration of cytokine administration, the
multiplicity of infection, the viral strain, and the cycles of viral infection. Interestingly, reductions in viral
DNAs could not fully account for the observed IFN-a-induced abrogation of progeny virion production. These
data, by our investigation of both single-cycle and spreading viral infections, support a predominant but not
exclusive effect of IFN-a on viral DNA synthesis.

viral nucleic acid synthesis and its transport to the host cell
nucleus during IFN treatments. We demonstrate that IFN's
action is mediated, in part, against viral reverse transcription.
Differences between viral isolates were quantitative and primarily related to the virus' ability to replicate in monocytes
rather than on differences in IFN's ability to restrict one isolate
more than another. The dosage of IFN in culture systems also
determined the level of viral restriction. Interestingly, quantitative reductions in viral nucleic acids could not completely
explain the abrogation of progeny virion production observed
in IFN-treated cells, indicating that IFN-a also influences viral
replication at stages beyond viral nucleic acid synthesis (1, 10,
13). These results support the argument for potential use of
IFN in therapies designed to restrict specific stages of the HIV
life cycle.
The ability of IFN-a to affect HIV infection in monocytes
was analyzed with two monocytotropic strains (HIV-1ADA and
HIV-lDJV) (16, 20) in primary human monocytes (Fig. 1). Both
HIV-1ADA and HIV-lDJv elicited a spreading infection in
monocytes. However, after the addition of 50 to 5,000 IU
of IFN-a per ml 18 h prior to HIV inoculation (with continuous exposure of the cells to IFN-at through 15 days), an
abrogation of progeny virion production (supernatant reverse transcriptase [RT] activity) was observed. Levels of RT
activity were reduced for HIV-lDJV compared with HIV-1ADA
levels at identical MOIs and without IFN-a treatment. Nevertheless, the responses to IFN-ot for both viral strains were
similar. These effects could not be explained by induction of
IFN-ot or -P by HIV-1, since no IFN-a or -, activity was
detected in culture fluids of monocytes infected with each of
the two viral strains during the course of infection (reference
13 and data not shown). IFN activity in culture fluids was
assayed by inhibition of cytopathic effects induced by vesicular
stomatitis virus in MDBK cells. Differentiation between IFN-ao
and
was performed by using their respective neutralizing
monoclonal antibodies placed into the MDBK cells together

Interferons (IFN) are important regulatory molecules for
host antiretroviral responses and viral pathogenesis (7, 10, 30,
31). Indeed, IFN is a first-line defense mechanism against
many animal viruses, including human immunodeficiency virus type 1 (HIV-1) (28, 30, 31). IFN activity in serum during
acute HIV seroconversion correlates with diminished levels of
virus and rising CD4+ T-cell numbers (28). These antiviral
actions of IFN are mediated by sets of IFN-inducible genes
that affect viral restriction but surprisingly remain poorly
defined for HIV-1 (11, 31, 33). Paradoxically, levels of alpha
IFN (IFN-a) in serum or surrogate markers for IFN activity
(neopterin, P2-microglobulin, 2',5'-oligoadenylate, and/or tubuloreticular inclusion bodies) correlate with HIV-1 plasma
viremia and progressive immunosuppression during the later
stages of viral infection (10). Thus, IFN plays a role both
in viral restriction and in pathogenesis during HIV-1 infection.
IFN is efficacious for treatment of patients with early-stage
HIV infection and those with Kaposi's sarcoma (6, 17, 23, 24).
Marked antiviral activities of IFN follow addition of IFN-at, -P,
and --y to HIV-1-infected T cells and monocytes (1, 10, 12, 13,
17, 19, 26, 30-34). How the HIV-1 life cycle is affected by IFN
treatment remains incompletely defined, and experimental
results vary among investigators. A review of these studies
suggests that IFN's actions are dependent on the in vitro
laboratory system, the viral strain, the target cells, the multiplicity of viral infection (MOI), the assay systems for virus
detection, and the type, concentration, and dosing intervals of
the IFNs (10, 30). To control for these variables and to better
define the mechanism of action of IFN against HIV-1, we used
a well-characterized monocyte cell system and varied the viral
strain, the MOI, and the concentrations of IFN to quantitate
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FIG. 1. Effects of continuous IFN-ot treatment on replication of HIV in monocytes. Peripheral blood mononuclear cells obtained by
leukopheresis were purified to >98% monocytes by centrifugal elutriation (16) and cultured for 7 days as adherent monolayers in medium with
human sera and macrophage colony-stimulating factor, a generous gift from Genetics Institute, Cambridge, Mass. Macrophage colony-stimulating
factor was removed from the medium, and cells were exposed for 18 h to recombinant IFN-ct2b (Schering Plough, Kenilworth, N.J.) from 0 to 5,000
IU/ml. Eighteen hours after IFN inoculation, the cells were exposed to either HIV-1ADA or HIV-lDjv at the MOI of 1 or 0.1. MOI measurements
were obtained by inoculating 10-fold dilutions of viral stock onto 7-day-cultured monocytes. All titrations were done in quadruplicate. After 21 days
postinoculation, viral replication was scored as positive if two of the following three criteria were met in 50% of the wells: (i) the presence of
virus-induced cytopathic effects (multinucleated giant cells and cell lysis), (ii) p24 antigen levels in culture fluids of 25 ng/ml, and (iii) RT activity
in culture fluids of 2 105 cpm/ml. For the data shown, IFN was maintained throughout the experimental time intervals. All cultures were refed with
fresh medium every 2 to 3 days. For RT activity, replicate samples of culture fluids were added to a reaction mixture of 0.05% Nonidet P-40 (Sigma
Chemical Co., St. Louis, Mo.), poly(A) (10 ,ug/ml), oligo(dT) (0.25 U/ml; Pharmacia, Piscataway, N.J.), 5 mM dithiothreitol (Pharmacia), 150 mM
KCl, 15 mM MgCl2, and 3H-dTTP (2 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) in Tris-HCl buffer (pH 7.9) for 24 h at 37°C. Radiolabeled
nucleotides were precipitated with cold 10% trichloroacetic acid and washed with 5% trichloroacetic acid and 95% ethanol in an automatic cell
harvester (Skatron Inc., Sterling, Va.) on glass filter discs. Radioactivity was estimated by liquid scintillation spectroscopy (22). HTLV-IIIB served
as positive control for the RT activity.
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with the experimental culture fluids or IFN control samples (1,
13).
We next determined whether the kinetics of progeny virion
production could be influenced by altering IFN-ao administration (Fig. 2). In these experiments, cells received a single dose
of IFN-ao, 50 to 5,000 IU/ml, 18 h prior to viral inoculation.
Monocytes were maintained in culture medium without exogenous IFN-ot during a 15-day observation period. These experiments demonstrated that the duration of IFN-ot treatment
played an important role in its ability to restrict viral replication. Indeed, a single dose of IFN-ao (50 to 5,000 IU/ml) 18 h
prior to virus infections showed a reduction but not abrogation
of RT activity. In this case, virus production was delayed by 3
to 5 days for both infections. Eventually, both viruses were able
to overcome the antiretroviral effects of IFN-ot. These data
indicate that the antiretroviral effects of IFN are contingent
upon the duration of IFN-ot treatment. The levels of viral
replication of either of the monocytotropic viral strains in
monocytes did not affect the antiretroviral effects or break-

0

through of virion production following single-dose IFN-ot
therapy.
We next examined whether the abrogation of virion production by IFN-ao was mediated by commensurate reductions in
rates of viral nucleic acid synthesis and its nuclear import.
Synthesis of early, intermediate, and late products of RT were
identified by PCR with primers to long terminal repeat (LTR)
U3/R, pol, LTR Rlgag, and LTR U5 regions of the viral
genome (3-5). The RT inhibitor zidovudine was also used to
assist in distinguishing de novo from preexisting virion-associated DNA (25, 35) (data not shown). Definitive evidence for
the presence of full-length plus- and minus-strand viral DNAs
was confirmed by analyzing the synthesis of two LTR circle
forms of episomal viral DNA. Although these episomal forms
of viral DNA do not represent provirus precursors, they are
formed only after synthesis of full-length viral DNA and its
transport to the host cell nucleus (2-5). Accumulation of early,
intermediate, and late products of reverse transcription including circle forms of viral DNA were thus examined in HIV-1-
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FIG. 2. Effects of single-dose IFN pretreatment on the replication of HIV in monocytes. Peripheral blood mononuclear cells obtained by
leukopheresis were purified to >98% monocytes by centrifugal elutriation and cultured for 7 days as adherent monolayers in medium with human
sera and macrophage colony-stimulating factor. After 7 days, the macrophage colony-stimulating factor was depleted and the cells were exposed
for 18 h in a single inoculation with 0 to 5,000 IU of recombinant IFN-ot. IFN was given as a single dose and was not maintained in the culture
fluids throughout the observation period. Eighteen hours after IFN treatment, the cells were inoculated with either HIV-1ADA or HIV-lDJv at an
MOI of 1 or 0.1 infectious virus per cell. All cultures were refed with fresh medium every 2 to 3 days. RT activity in culture supernatants was
determined as described in the legend for Fig. 1.

2

infected cells during IFN-cr treatment. De novo synthesis levels
of early products of reverse transcription were similar for both
HIV-lDJV- and HIV-1ADA-infected monocytes and quantitatively reduced after IFN-ot (50 to 5,000 IU/ml) treatment.
Modest changes (Fig. 3A; Table 1) were shown after treatment
with c5,000 IU of IFN-oa, indicating that no marked inhibition
of early stages in virus replication (binding, fusion, or strong
stop DNA synthesis) occurred in the presence of IFN (Fig. 3).
Synthesis of intermediate and late reverse transcription intermediates was affected by IFN-a treatments in both HIV-lADAand HIV-1DJV-infected monocytes (Fig. 3). More pronounced
reduction of intermediate and late products of reverse tran-

scription than of early viral cDNA products was evident for
both HIV-lDJv and HIV-1ADA. The reduction in abundance of
intermediate and late products of reverse transcription in the
presence of IFN was more pronounced at a lower MOI (Fig.
3B; Table 2). In this instance, viral nucleic acid synthesis and its
transport to the monocyte nucleus were almost abrogated by
cell treatments of -500 IU of IFN-a1.
The contribution of virion-associated DNA (35, 36) was
excluded by comparing levels of viral DNA synthesis in monocytes in the presence and absence of zidovudine. The episomal
forms of viral DNA containing two LTR circles were detected
within 24 h postinfection in both

HIV-1ADA- and HIV-lDJV-

infected cells (Fig. 3A); in the lower-MOI assay (Fig. 3B),
these episomal forms were detected after 48 and 72 h in
HIV-lADA- and HIV-1DJV-infected cells, respectively. This
result suggests that under the culture conditions and MOI used
in this study viral DNA synthesis was complete within 72 h.
Little virion-associated DNA was observed in cultures at early
times postinfection, and as a consequence, little if any viral
DNA accumulation was observed in monocyte cultures treated
with zidovudine (data not shown). Early, intermediate, and
late products of reverse transcription were evident by 8 h
postinfection with HIV-1ADA, and accumulation of late products of RT were delayed in HIV-1DJv-infected cells. We do not
attach much significance to the observed quantitative differences in reverse transcription between the two isolates and
conclude that viral DNA synthesis proceeds rapidly to completion in monocytes infected with both viral strains. The inhibition of synthesis of the intermediate and late products of
reverse transcription was dependent on the IFN-ot dose. This
inhibition was more marked with the HIV-lDJV strain, suggesting altering responses of specific viral strains to IFN-oL. Quantitatively, the extent of viral cDNA synthesis, as measured by
copy numbers, in the presence of IFN-ot, is summarized in
Tables 1 and 2. Here, HIV-1 copy numbers within virusinfected monocytes treated with IFN-ot for 48 h (Fig. 3), were
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FIG. 3. Synthesis of viral DNA in HIV-1-infected monocytes following IFN treatment. Monocytes were infected with HIV-1 at an MOI of 1
(A) or 0.1 (B). At the indicated times postinfection, monocytes were removed by scraping from Costar six-well plates (initially seeded with 3 x
106 monocytes per plate) for isolation of total cellular DNA and analysis by PCR. From 0 to 5,000 IU of IFN-a was added to monocyte cultures
18 h prior to infection and was maintained in the culture medium throughout the period of experimental analyses. DNA from cells obtained from
one well of the six-well Costar plate was subjected to 30 cycles of PCR with primers to LTR U3 and R (coordinates 9194 to 9214 and 9591 to 9610
of HIV HXB2 (3-5); polI and poll (coordinates 2131 to 2149 and 2592 to 2610, respectively). LTR R and gag (coordinates 9194 to 9214 and 794
to 815, respectively) for amplification of early, intermediate, and late reverse transcription products, respectively. Amplification of episomal forms
of viral DNA containing two LTRs was performed by using LTR R and U5 (coordinates 9591 to 9610 and 9650 to 9679, respectively) primers. For
the LTR primers, only 3' LTR coordinates are given. PCR amplification products were visualized after Southern blot transfer and hybridization
with 32P-labeled oligonucleotide probes (20). Hybridized blots were visualized on a molecular Phosphorimager SF (Molecular Dynamics).
Standards for LTR U3/R, polI/J, and LTR R/gag products were generated by PCR on doubling dilutions of DNA from 8E5 cells which contain
one defective viral genome per cell (9). Standards for the two LTR circle forms of viral DNA were generated from doubling dilutions of
HIV-1-infected CD4+ MT-4 cells. Tubulin served as an internal cellular standard for all samples assayed; *, numbers represent cell equivalents.
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TABLE 1. Quantitative effects of IFN-cx treatment on HIV-1 reverse transcriptsa
Viral DNA copy no. (fold reduction) for HIV-1 strain and IFN-as dose

HIV 1DJV

HIV-1ADA

MOI-1
0

LTR U3/R (early), 103
polI/J (intermediate)
LTR R/gag (late)
LTR R/U5 (2 LTR circles), 103

58.4
518

1,746
185

50

500

5,000

0

50

500

5,000

19.6 (2.9)
323 (1.6)

18.6 (3.1)
190 (2.7)
636 (2.7)
11.9 (15.5)

14.1 (4)
107 (4.8)
392 (4.4)
3 (61)

50.5
262
802
244

37.5 (1.3)
143 (1.8)
128 (6.2)
63 (3.9)

31.5 (1.6)
76 (3.4)
44 (18.2)
3 (81)

21.4 (2.3)
27 (9.7)
22 (36.4)
3 (81)

1,007 (1.7)
34 (5)

a Hybridized blots were visualized on a molecular Phosphoimager SF (Molecular Dynamics). To generate copy numbers, total counts were obtained from the 48-h
time point of the hybridized blots and compared with known standards for LTR U3/R, po1I/J, and LTR R/gag products generated by PCR on doubling dilutions of DNA
from 8E5 cells (9). Linear curves were established from the 8E5 cells to generate the copy numbers shown. Standards for the two LTR circle forms of viral DNA were
generated from doubling dilutions of HIV-1-infected CD4+ MT-4 cells. Doses are measured in international units per milliliter.

quantitatively reduced and dependent on the IFN-a concentration. These results, taken together, demonstrate that IFN
treatment of monocytes quantitatively diminishes the synthesis
of all products of reverse transcription while preferentially
affecting intermediate and late viral cDNA synthesis. The
data are in agreement with our previous observations regarding the antiviral effects of IFN-ot, in monocytes, including
but not limited to the level of HIV-1 reverse transcription (1,
13).
IFN-induced restriction of the early events of the viral
replication cycle in murine and avian retroviral infections, resulting in reduced efficiency of host cell transformation, have already been reported (31). Previous studies with
HIV-1 demonstrated that IFN inhibits early and terminal
events of viral replication, including nucleic acid synthesis,
assembly, and budding of progeny virions, resulting in abortive infections or the formation of defective particles attached
to host cell membranes (1, 10, 12, 13, 17, 19, 26, 30-34). In
the present study, both early (viral cDNA synthesis) and
late (progeny virion production) events of viral replication
were analyzed and indicated that the reduction in virus production could not be accounted for solely by the observed
reductions in viral DNA synthesis. This work is in agreement with previous published observations (26, 32) which
indicate that IFN-a inhibition of HIV-1 replication is manifest predominantly at the level of viral cDNA synthesis.
However, data presented in this study strongly support the
notion that antiviral actions of IFN-az extend beyond the
inhibition of RT. The use of single-cycle infections to measure
viral nucleic acid synthesis and its nuclear transport coupled
with measurements of spreading viral infections verify IFN-a's

ability to restrict HIV-1 replication beyond viral cDNA synthesis. The importance of this work is that it reconciles, in
part, the seemingly disparate reports (1, 10, 12, 13, 17, 19, 26,
30-34) concerning IFN-a's antiviral actions in HIV-1-infected
cells.
The use of monocytes as indicator cells in laboratory assays
provides a unique model for IFN-ot antiretroviral actions.
IFN-a markedly restricts HIV-1 replication in monocytes
at levels sometimes exceeding those in CD4+ T cells (13,
19, 26, 30). IFN-a is produced, in large measure, by monocytes (10). Most importantly, monocytes and macrophages
are a major tissue reservoir for HIV-1 in the infected human host (14). There remains little doubt that the ability
of IFN-a to restrict viral replication in macrophages has
potential importance for treatment strategies in infected
individuals (17). Virus-host cell interactions are unique in
macrophages (16, 21, 29), since they are dependent not only on
the viral strain (16, 21, 29) but on host cell differentiation
and/or maturation (15, 27) and cytokines produced as a
consequence of HIV-1 infection (7). Indeed, IFN-a and -,
are regulated by cell-to-cell interactions between HIV-1infected monocytes or T cells and peripheral blood mononuclear cells or by direct effects of the viral envelope protein gpl20 (12, 18). Early events of viral replication (during
or before acute seroconversion) may be controlled, in part,
by IFN (28). Only later during advanced viral infection
and immunosuppression do HIV-1 mutants with apparent
IFN resistance phenotypes likely emerge (20, 30a). The presence of IFN resistance phenotypes of HIV-1 could circumvent antiviral actions of IFN. At the same time, these viruses
could retain the ability to induce IFN within infected individ-

TABLE 2. Quantitative effects of IFN-a treatment on HIV-1 reverse transcriptsa
Viral DNA copy no. (fold reduction) for HIV-1 strain and IFN-a dose

MOI-1
0

LTR U3/R (early), 103
polI/J (intermediate)
LTR Rlgag (late)
LTR R/U5 (2 LTR circles), 103

HIV-lDJV

HIV-1ADA
20.9
344

1,444
50

50

1 (20.9)

28 (12.2)
286 (5)
20 (2.5)

500

3.3 (6.3)
21 (16.3)
164 (8.8)
0

5,000

3.7 (5.6)
8 (43)
77 (18.7)
0

0

50

500

5,000

30.8
146
135
16

12.9 (2.4)
37 (3.9)
19 (7)
0

8.9 (3.5)
10 (14.6)
4 (33.7)
0

8.7 (3.5)
5 (29.2)
0
0

a
Hybridized blots were visualized on a molecular Phosphoimager SF (Molecular Dynamics). To generate copy numbers, total counts were obtained from the 48-h
time point of the hybridized blots and compared with known standards for LTR U3/R, polIIJ, and LTR R/gag products generated by PCR on doubling dilutions of DNA
from 8E5 cells (9). Linear curves were established from the 8E5 cells to generate the copy numbers shown. Standards for the two LTR circle forms of viral DNA were
generated from doubling dilutions of HIV-1-infected CD4+ MT-4 cells. Doses are measured in international units per milliliter.
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uals. The inevitable outcome of this virus-macrophage-cytokine interaction is high levels of plasma viremia coordinate
with high titers of IFN-a and leading to advanced clinical
disease (17, 30).
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